Ruxolitinib: evolution or revolution in treatment of patients with polycythemia vera?

被引：1

作者：

Beauverd, Yan ^{[1
]}

McLornan, Donal P. ^{[1
,2
]}

Radia, Deepti H. ^{[1
]}

Harrison, Claire N. ^{[1
]}

机构：

[1] Guys & St Thomas NHS Fdn Trust, Dept Hematol, London, England

[2] Kings Coll Hosp NHS Fdn Trust, Dept Hematol Med, London, England

来源：

FUTURE ONCOLOGY | 2016年 / 12卷 / 06期

关键词：

myeloproliferative neoplasms; outcomes; polycythemia vera; ruxolitinib; treatment; ESSENTIAL THROMBOCYTHEMIA; JAK INHIBITION; PRIMARY MYELOFIBROSIS; CELL-FUNCTION; LOW TOXICITY; HYDROXYUREA; SAFETY; HYDROXYCARBAMIDE; PHARMACOKINETICS; INTOLERANCE;

D O I：

10.2217/fon-2015-0023

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Current treatments for polycythemia vera have remained unchanged for decades with phlebotomy, hydroxycarbamide (also named hydroxyurea) and to a lesser extent interferon being the cornerstones in our therapeutic armamentarium. However, some patients do not respond to, or indeed experience significant side effects to, these current agents and development of alternative therapeutic options is required. Ruxolitinib, a potent JAK1/2 inhibitor, initially approved for myelofibrosis, was recently approved for patients with polycythemia vera refractory or intolerant to hydroxycarbamide. In this article, we review the currently available efficacy and safety data.

引用

页码：739 / 749

页数：11

共 50 条

[1] Ruxolitinib for the treatment of patients with polycythemia vera
Kiladjian, Jean-Jacques
Winton, Elliott F.
Talpaz, Moshe
Verstovsek, Srdan
EXPERT REVIEW OF HEMATOLOGY, 2015, 8 (04) : 391 - 401
[2] Ruxolitinib for treatment of polycythemia vera
Cherington, Chad C.
Gowin, Krisstina L.
Mesa, Ruben A.
EXPERT OPINION ON ORPHAN DRUGS, 2015, 3 (09): : 1085 - 1096
[3] Ruxolitinib: a targeted treatment option for patients with polycythemia vera
Vaddi, Kris
Verstovsek, Srdan
Kiladjian, Jean-Jacques
BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY, 2016, 6 : 7 - 19
[4] The advantages and risks of ruxolitinib for the treatment of polycythemia vera
Colafigli, Gioia
Scalzulli, Emilia
Pepe, Sara
Di Prima, Alessio
Efficace, Fabio
Martelli, Maurizio
Foa, Robin
Breccia, Massimo
EXPERT REVIEW OF HEMATOLOGY, 2020, 13 (10) : 1067 - 1072
[5] A safety evaluation of ruxolitinib for the treatment of polycythemia vera
Boldrini, Valentina
Vannucchi, Alessandro M.
Guglielmelli, Paola
EXPERT OPINION ON DRUG SAFETY, 2024, 23 (01) : 1 - 7
[6] Anagrelide hydrochloride and ruxolitinib for treatment of polycythemia vera
Kremyanskaya, Marina
Mascarenhas, John
Hoffman, Ronald
EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (08) : 1185 - 1194
[7] Ruxolitinib for treatment of polycythemia vera and myelofibrosis in patients after liver transplantation
Dold, Leona
Lutz, Philipp
Heine, Annkristin
Weismuller, Tobias J.
Strassburg, Christian P.
Spengler, Ulrich
CLINICAL CASE REPORTS, 2021, 9 (09):
[8] THERAPY OF THE POLYCYTHEMIA VERA WITH RUXOLITINIB
Melikyan, A. L.
Subortseva, I. N.
Gilyazitdinova, E. A.
Kovrigina, A. M.
Sudarikov, A. B.
Abdullaev, A. O.
GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2017, 62 (04): : 229 - 232
[9] Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
Vannucchi, Alessandro M.
Kiladjian, Jean Jacques
Griesshammer, Martin
Masszi, Tamas
Durrant, Simon
Passamonti, Francesco
Harrison, Claire N.
Pane, Fabrizio
Zachee, Pierre
Mesa, Ruben
He, Shui
Jones, Mark M.
Garrett, William
Li, Jingjin
Pirron, Ulrich
Habr, Dany
Verstovsek, Srdan
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (05): : 426 - 435
[10] TREATMENT WITH RUXOLITINIB IN MYELOFIBROSIS AND POLYCYTHEMIA VERA EXPERIENCE OF A CENTRE
Moya Arnao, M.
Perez Lopez, R.
Martinez Marin, A.
Fernandez Poveda, E.
Navarro Almenzar, B.
Berenguer Piqueras, M.
Cabanas Perianes, V
Salido Fierez, E.
Moreno Belmonte, M. J.
Cerezo Manchado, J. J.
Labbadia, F.
Blanquer Blanquer, M.
Garcia Hernandez, A. M.
Martinez Garcia, A. B.
Melero Amor, A.
Rosique Cortina, P.
Ruiz Sanchez, M.
Moraleda Jimenez, J. M.
HAEMATOLOGICA, 2017, 102 : 332 - 333

← 1 2 3 4 5 →